Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

**What Happened:** This case involved a dispute between two pharmaceutical companies - Caraco Pharmaceutical Laboratories and Novo Nordisk - over drug patents. Novo Nordisk had listed a patent with the FDA that Caraco believed was improperly filed under the Hatch-Waxman Act, a law that governs how generic drug companies can challenge brand-name drug patents. Caraco wanted to produce a generic version of Novo Nordisk's diabetes medication but argued that Novo Nordisk's patent listing was deficient and shouldn't prevent them from entering the market. **What the Court Decided:** The Supreme Court sided with Caraco, reversing a lower court's decision. The Court ruled that Novo Nordisk's patent listing was indeed deficient under the Hatch-Waxman Act and that Caraco was entitled to a court declaration that they weren't infringing on any valid patent. **Why This Matters for Workers:** While this case directly involved pharmaceutical companies, it impacts workers by potentially making generic medications more accessible and affordable. When generic drug companies can more easily challenge improper patent listings, it can lead to lower prescription drug costs, which benefits workers and their families who rely on employer health insurance or pay for medications out-of-pocket.